Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection

• Published in: The Korean journal of internal medicine 2015, 30(4), , pp.550-553
• Main Authors: Lee, Na-Ri, Jang, Ji Won, Kim, Hee Sun, Yhim, Ho-Young
• Format: Article
• Language: English
• Subjects: Adult; Antineoplastic Agents - adverse effects; Antitubercular Agents - therapeutic use; Biopsy; Female; Gastrointestinal Stromal Tumors - drug therapy; Gastrointestinal Stromal Tumors - pathology; Gastrointestinal Stromal Tumors - surgery; Humans; Imatinib Mesylate - adverse effects; Letter to the Editor; Lung Diseases, Interstitial - chemically induced; Lung Diseases, Interstitial - diagnosis; Mycobacterium tuberculosis - isolation & purification; Protein Kinase Inhibitors - adverse effects; Rectal Neoplasms - drug therapy; Rectal Neoplasms - pathology; Rectal Neoplasms - surgery; Tomography, X-Ray Computed; Tuberculosis, Pulmonary - diagnosis; Tuberculosis, Pulmonary - drug therapy; Tuberculosis, Pulmonary - microbiology; 내과학
• ISSN: 1226-3303; 2005-6648
• DOI: 10.3904/kjim.2015.30.4.550

In conclusion, we presented a rare case of ILD associated with IM therapy in a patient with GIST. It is important to have a high index of suspicion for this rare pulmonary toxicity when patients, in particular with preexisting lung disease, have unexplained lung infiltrates regardless of pulmonary symptoms if they are receiving the IM. The early evaluation with chest computed tomography and prompt withdrawal of IM with or without the use of corticosteroid is needed to avoid further detrimental effects of the drug. Furthermore, prospective study is needed to investigate the incidence of IM-induced ILD in patients with prior history of M. tuberculosis infection. KCI Citation Count: 4